178 related articles for article (PubMed ID: 35550440)
1. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant.
Sidana S; Dueck AC; Thanarajasingam G; Griffin JM; Thompson C; Durani U; Burtis M; Warsame R; Paludo J; Gertz MA; Dispenzieri A; Ansell SM; Rajkumar SV; Yost K; Bennani N; Lin Y; Kumar S
Transplant Cell Ther; 2022 Aug; 28(8):473-482. PubMed ID: 35550440
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS
Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
[TBL] [Abstract][Full Text] [Related]
5. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
6. Quality of Life, Physical Functioning, and Psychological Distress of Older Adults Undergoing Hematopoietic Stem Cell Transplantation.
Newcomb R; Johnson PC; Cronin K; Choe JJ; Holmbeck K; Nabily A; Lark P; Rabideau DJ; DeFilipp Z; Chen YB; El-Jawahri A
Transplant Cell Ther; 2023 Jun; 29(6):387.e1-387.e7. PubMed ID: 36958693
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
Fung HC; Cohen S; Rodriguez R; Smith D; Krishnan A; Somlo G; Sahebi F; Senitzer D; O'Donnell MR; Stein A; Snyder DS; Spielberger R; Bhatia R; Falk P; Molina A; Nademanee A; Parker P; Kogut N; Popplewell L; Vora N; Margolin K; Forman SJ
Biol Blood Marrow Transplant; 2003 Oct; 9(10):649-56. PubMed ID: 14569561
[TBL] [Abstract][Full Text] [Related]
9. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy.
Johnson PC; Dhawale T; Newcomb RA; Amonoo HL; Lavoie MW; Vaughn D; Karpinski K; El-Jawahri A
Blood Adv; 2023 Jul; 7(14):3541-3550. PubMed ID: 36995091
[TBL] [Abstract][Full Text] [Related]
12. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
[TBL] [Abstract][Full Text] [Related]
13. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
El-Jawahri A; LeBlanc T; VanDusen H; Traeger L; Greer JA; Pirl WF; Jackson VA; Telles J; Rhodes A; Spitzer TR; McAfee S; Chen YA; Lee SS; Temel JS
JAMA; 2016 Nov; 316(20):2094-2103. PubMed ID: 27893130
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E
Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986
[TBL] [Abstract][Full Text] [Related]
15. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease.
Patel SS; Hong S; Rybicki L; Farlow S; Dabney J; Kalaycio M; Sobecks R; Majhail NS; Hamilton BK
Transplant Cell Ther; 2023 Jul; 29(7):465.e1-465.e7. PubMed ID: 37003415
[TBL] [Abstract][Full Text] [Related]
17. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux C; Johnston LJ; Lowsky R; Muffly LS; Craig JK; Shiraz P; Rezvani A; Frank MJ; Weng WK; Meyer E; Shizuru J; Arai S; Negrin R; Miklos DB; Sidana S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e328-e332. PubMed ID: 32961371
[TBL] [Abstract][Full Text] [Related]
18. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.
Robinson S; Dreger P; Caballero D; Corradini P; Geisler C; Ghielmini M; Le Gouill S; Kimby E; Rule S; Vitolo U; Dreyling M; Hermine O;
Leukemia; 2015 Feb; 29(2):464-73. PubMed ID: 25034148
[TBL] [Abstract][Full Text] [Related]
19. Parent Psychological Distress Is Associated with Symptom Burden and Health-Related Quality of Life in Children and Adolescents Undergoing Stem Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy.
Ward J; Smith J; Powers K; Hellsten M; Murray P
Transplant Cell Ther; 2023 Jul; 29(7):462.e1-462.e9. PubMed ID: 37086850
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
